Phio Pharmaceuticals (PHIO) Assets Average (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Assets Average came in at $19.4 million in Q1 2026, up 102.83% YoY from $9.6 million in Q1 2025, and up 17.9% on a QoQ basis from $16.5 million in Q4 2025.
Phio Pharmaceuticals (PHIO) Assets Average (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Assets Average data on file, last reported at $19.4 million in Q1 2026.
- Quarterly Assets Average rose 102.83% year-over-year to $19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (up 102.83% YoY) and the FY2025 annual result came in at $13.6 million, up 80.27% from the prior year.
- Assets Average rose to $19.4 million in Q1 2026, from $16.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $23.7 million in Q1 2022 to a low of $5.5 million in Q2 2024.
- A 5-year average of $12.6 million and a median of $11.3 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average sank 52.42% — and 2025, when it jumped 184.34%.
- Tracing PHIO's Assets Average over 5 years: stood at $14.3 million in 2022, then plunged by 33.92% to $9.5 million in 2023, then sank by 38.62% to $5.8 million in 2024, then jumped by 184.34% to $16.5 million in 2025, then advanced by 17.9% to $19.4 million in 2026.
- The last three Assets Average figures came in at $19.4 million (Q1 2026), $16.5 million (Q4 2025), and $11.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | 15.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.86 Mn |
| Mar 31, 2026 | 19.45 Mn |
| Dec 31, 2025 | 16.50 Mn |
| Sep 30, 2025 | 11.40 Mn |
| Jun 30, 2025 | 12.37 Mn |
| Mar 31, 2025 | 9.59 Mn |
| Dec 31, 2024 | 5.80 Mn |
| Sep 30, 2024 | 5.58 Mn |
| Jun 30, 2024 | 5.52 Mn |
| Mar 31, 2024 | 7.55 Mn |
| Dec 31, 2023 | 9.45 Mn |
| Sep 30, 2023 | 10.92 Mn |
| Jun 30, 2023 | 11.00 Mn |
| Mar 31, 2023 | 11.26 Mn |
| Dec 31, 2022 | 14.30 Mn |
| Sep 30, 2022 | 17.97 Mn |
| Jun 30, 2022 | 21.15 Mn |
| Mar 31, 2022 | 23.67 Mn |
| Dec 31, 2021 | 26.56 Mn |
| Sep 30, 2021 | 29.80 Mn |